ethamsylate
Small moleculeexperimental
Etamsylate is an antihemorrhagic agent which is believed to work by increasing resistance in the endothelium of capillaries and promoting platelet adhesion. It also inhibits biosynthesis and action of those prostaglandins which cause platelet disaggregation, vasodilation and increased capillary permeability. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Nov 1, 2015 (NCT02604719)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- P-selectinACTIVATOR
SELP activator
Chemistry & pharmacology
Loading structure…
SMILES
CCNCC.O=S(=O)(O)c1cc(O)ccc1O- Mol. weight
- 263.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEtamsylate ↗
- ChEMBLCHEMBL1514715 ↗
Also known as
- cyclonamine
- dicinone
- dicynene
- dicynene
- dicynene 1000
- dicynone
- dicynone
- diethylammonium 2,5-dihydroxybenzenesulfonate
- e-141
- e-141
- etamsylate
- etamsylate
- etamsylate
- ethamsylate
- ethamsylate
- ethamsylate
- ethamsylate
- ethamsylate
- ethamsylate
- md-141
- md-141
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06190535 | N/A | Jan 1, 2024 | University of Sfax |
| NCT05806307 | Phase 4 | Mar 15, 2023 | Cairo University |
| NCT02604719 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Ain Shams University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Sfax | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1